Both SPHK1 and SPHK2 were found to be elevated in the MCL cell line SP53, and inhibition of S1PR1 or knockdown of SPHK1 in SP53 and Jeko-1 cells enhanced NKT cell activation and NKT response against MCL. Here, SPHK2 is linked to mantle cell lymphoma.